<DOC>
	<DOC>NCT00658099</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.</brief_summary>
	<brief_title>Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes HbA1c greater than 7.0% and/or hypoglycaemia variable FBG and/or weight increase the selection of the subjects will be at the discretion of the participating physician nontype 2 diabetes current treatment with Levemir® or Insulatard® hypersensitivity to Levemir® or Insulatard® or to any of the excipients women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>